Prognostic factors and survival outcomes in older adults with extensive-stage small cell lung cancer: A multicenter retrospective cohort study
Authors:
- Sermin Dinc SonusenSSSermin Dinc Sonusen
- Zehra Sucuoglu IsleyenZIZehra Sucuoglu Isleyen
- Naime Afsar SatisNSNaime Afsar Satis
- Mesut YilmazMYMesut Yilmaz
- Bekir DoganBDBekir Dogan
- Senar GunencSGSenar Gunenc
- Tanju BerberTBTanju Berber
- Berna Akkus YildirimBYBerna Akkus Yildirim
- Yaren Ceran BasYBYaren Ceran Bas
- Merve Ekinci FidanMFMerve Ekinci Fidan
- Resit AkyelRAResit Akyel
- Kayhan ErturkKEKayhan Erturk
Open Access
- 8 May 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (19) , e48711
Abstract
Extensive-stage small cell lung cancer (ES-SCLC) in older adults is associated with poor outcomes, and optimal management in this population remains challenging. This study aimed to identify clinical and treatment-related factors associated with survival in patients aged ≥70 years with ES-SCLC. A retrospective multicenter cohort study included 135 older adults (aged ≥70 years) diagnosed with ES-SCLC across 3 tertiary centers. All patients received at least 1 cycle of platinum–etoposide–based chemotherapy. Demographic, clinical, and treatment variables – including metastatic sites, number of chemotherapy cycles, thoracic radiotherapy (TRT), prophylactic cranial irradiation, and palliative radiotherapy to extracranial metastases – were collected. Survival outcomes were estimated using the Kaplan–Meier method and compared using the log-rank test. Prognostic factors for progression-free survival and overall survival (OS) were evaluated using Cox proportional hazards regression models. The median age was 73.2 years; 88.1% of patients were male. The objective response rate was 69.9%. Median progression-free survival and OS were 7.1 and 8.3 months, respectively (95% CI: 6.09–8.17 and 7.67–8.93). In multivariate analysis, Eastern Cooperative Oncology Group performance status ≥2 ( P <.001), liver metastases ( P = .006), fewer than 4 chemotherapy cycles ( P <.001), absence of prophylactic cranial irradiation ( P = .028), and lack of palliative radiotherapy to extracranial metastases ( P <.001) were independently associated with shorter OS. TRT did not retain statistical significance in multivariate analysis. Only 34.1% of patients received second-line therapy. The 1-year and 2-year OS rates were 33% and 12%, respectively. Fit older adults (Eastern Cooperative Oncology Group performance status 0–1) may derive meaningful survival benefit from multimodal treatment strategies. Treatment decisions should be individualized based on functional status rather than chronological age alone. Prospective studies incorporating comprehensive geriatric assessment are warranted.Keywords
This publication has 30 references indexed in Scilit:
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Prophylactic cranial irradiation or no prophylactic cranial irradiation in metastatic small cell lung cancer: is it a relevant question once again?Journal of Thoracic Disease, 2017
- Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trialThe Lancet Oncology, 2017
- Prognostic effect of liver metastasis in lung cancer patients with distant metastasisOncotarget, 2016
- Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trialThe Lancet, 2015
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesThe Lancet, 2007
- Prophylactic Cranial Irradiation in Extensive Small-Cell Lung CancerNew England Journal of Medicine, 2007
- Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease?Lung Cancer, 2002
- Toxicity and response criteria of the Eastern Cooperative Oncology GroupAmerican Journal of Clinical Oncology, 1982